Core Viewpoint - The company is providing guarantees for its subsidiaries to secure a total bank credit line of up to 7.765 billion RMB to support their operational needs [1][4]. Group 1: Guarantee Overview - The company has approved a total guarantee amount of 4.25 billion RMB for its subsidiaries, which will be provided as joint liability guarantees [3]. - The guarantee is aimed at meeting the operational development needs of the subsidiaries, which are performing normally and have stable financial conditions [3][4]. Group 2: Subsidiary Information - The subsidiaries involved in the guarantee include: - Luoyang Daclin Pharmaceutical Co., Ltd. - Xuchang Daclin Baoyuantang Pharmacy Chain Co., Ltd. - Henan Daclin Pharmaceutical Logistics Co., Ltd. - Guangxi Daclin Pharmaceutical Co., Ltd. - Wuzhou Daclin Chain Pharmacy Co., Ltd. - Daclin (Zhejiang) Pharmaceutical Co., Ltd. - Foshan Daclin Pharmaceutical Trading Co., Ltd. [2] Group 3: Financial Metrics - As of the announcement date, the total external guarantee balance of the company and its subsidiaries is 42.575 billion RMB, which accounts for 52.31% of the latest audited net assets attributable to shareholders [5].

证券代码：603233 证券简称：大参林 公告编号：2025-059 大参林医药集团股份有限公司 一、担保情况概述 （一）担保的基本情况 为满足子公司的日常经营发展的资金需求，近日，公司就子公司向银行申 请综合授信提供担保，具体情况如下： | 担保 | 被担保人 | 担保金额 | 授信机构 | 担保类 | 反担保 | 期限 | | --- | --- | --- | --- | --- | --- | --- | | 人 | | （万元） | | 型 | 情况 | | | 公司 | 河南大参林医药物流有 | 6,000 | 兴业银行股份有限公 | 连带责 | 无 | 以实际签署 | | | 限公司 | | 司郑州分行 | 任担保 | | 的合同为准 | 担保对象及基本情况 | | | 被担保人名称 | 河南大参林医药物流有限公司、漯河市 | | | | --- | --- | --- | --- | --- | --- | | | | | 大参林医药有限公司等 | | 7 家控股子公司 | | 担 | 保 对 | 本次担保金额 | | 42,500 万元 | | | 象 | | 实际为其提供的担保余额 | 1 ...

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 20.3 yuan [2][8]. Core Insights - The company demonstrated stable revenue growth with a 1.3% year-on-year increase in revenue to 13.52 billion yuan in the first half of 2025, while net profit attributable to shareholders rose by 21.4% to 800 million yuan [2][8]. - The growth in revenue is attributed to the performance of existing stores and contributions from newly opened and franchised stores, while profit growth is driven by revenue increase, improved management efficiency, and effective control of total operating costs [2][8]. - The company is focusing on high-quality development and expanding its presence in Southern China while dynamically optimizing its store network [2][8]. Financial Performance - In the first half of 2025, the company had a total of 16,833 stores, a 4.2% increase year-on-year, with a decrease in direct-operated stores by 3.7% and a 20.2% increase in franchised stores [2][8]. - The retail pharmacy business generated revenue of 11 billion yuan, a slight decline of 0.5% year-on-year, while the gross margin improved by 0.4 percentage points to 37.6% [2][8]. - The company’s net profit margin increased to 6.3%, up by 1.0 percentage points year-on-year, indicating effective cost control measures [2][8]. Future Projections - The report adjusts the company's net profit forecasts for 2025-2027 to 1.16 billion yuan, 1.33 billion yuan, and 1.53 billion yuan, respectively, with year-on-year growth rates of 27%, 15%, and 15% [2][8]. - The projected earnings per share (EPS) for 2025 is 1.02 yuan, with a price-to-earnings (P/E) ratio of 20 times [2][8].

Investment Rating - The report maintains an "Outperform" rating for the biopharmaceutical industry [1] Core Viewpoints - The growth of healthcare expenses, which reached 9.06 trillion yuan in 2023, is outpacing GDP growth, indicating that commercial health insurance may provide a solution to the pressures faced by the medical insurance system [3][15] - The commercial health insurance sector is expected to grow significantly, with premiums projected to reach 97.74 billion yuan by 2024, driven by low penetration rates and the need for additional funding sources [20][24] - Policies are increasingly supportive of commercial health insurance, particularly in relation to innovative drugs, which are now being included in the commercial health insurance directory [71][76] Summary by Sections Part 1: Healthcare Financing System - The healthcare financing system in China consists of government, social, and personal contributions, with social contributions being the main driver for future growth [10][15] Part 2: Growth of Health Insurance - The commercial health insurance market is expected to fill a significant funding gap, with an estimated shortfall of over 1.7 trillion yuan by 2030 [21][22] - Medical insurance is the primary source of compensation within commercial health insurance, with a compensation rate of approximately 68.79% in 2022 [27][31] Part 3: Core Products of Medical Insurance - The report highlights the importance of medical insurance as a key focus area, noting that it directly compensates for medical expenses, unlike critical illness insurance [31][35] Part 4: Policy Support for Health Insurance Development - A series of policies since 2009 have aimed to promote the development of commercial health insurance, with specific targets for market size and coverage [71][72] Part 5: Investment Recommendations - The report suggests focusing on innovative drug companies with rich pipelines, DTP pharmacies, and companies in the TPA industry, as well as innovative medical devices and high-end medical service providers [77]

Company Overview - Dazhonglin Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, established on February 12, 1999, and listed on July 31, 2017 [2] - The company's main business includes retail of traditional Chinese and Western medicines, health products, medical devices, and other goods, with revenue composition as follows: Western and Chinese medicines 76.88%, non-pharmaceuticals 10.49%, Chinese medicinal materials 9.75%, and others 2.88% [2] Financial Performance - For the first half of 2025, Dazhonglin achieved operating revenue of 13.523 billion yuan, a year-on-year increase of 1.33%, and a net profit attributable to shareholders of 798 million yuan, a year-on-year increase of 21.38% [2] - Since its A-share listing, Dazhonglin has distributed a total of 3.355 billion yuan in dividends, with 1.624 billion yuan distributed in the last three years [3] Stock Performance - As of September 22, Dazhonglin's stock price decreased by 2.02% to 16.99 yuan per share, with a total market capitalization of 19.349 billion yuan [1] - Year-to-date, the stock price has increased by 15.19%, with a decline of 1.74% over the last five trading days and a 0.70% decline over the last 20 days [2] - The stock has seen a 4.23% increase over the last 60 days [2] Shareholder Information - As of June 30, 2025, the number of shareholders is 31,500, a decrease of 10.07% from the previous period, with an average of 36,097 circulating shares per person, an increase of 11.20% [2] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 90.448 million shares, an increase of 12.4318 million shares from the previous period [3] Market Activity - On September 22, the net outflow of main funds was 3.2502 million yuan, with large orders buying 4.3386 million yuan (5.52% of total) and selling 7.5887 million yuan (9.66% of total) [1]

一、说明会类型 证券代码：603233 证券简称：大参林 公告编号：2025-058 大参林医药集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 19 日(星期五)至 9 月 25 日(星期四)16:00 前登录上 证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 DSL1999@dslyy.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 大参林医药集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日 发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度的经营情况及财务状况，公司计划于2025年9月26日下午16:00-17:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 本次业绩说明会以网络互动形式召开，公司将针 ...

Market Performance - The pharmaceutical commercial sector increased by 0.17% compared to the previous trading day, with XD Yifeng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.34, up 0.37%, while the Shenzhen Component Index closed at 13215.46, up 1.16% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with XD Yifeng Pharmaceutical closing at 26.22, up 2.66%, and Dazhenglin at 17.66, up 2.56% [1] - Other notable performers included Liuyao Group at 18.90, up 1.02%, and China Pharmaceutical at 10.95, up 0.83% [1] Trading Volume and Value - XD Yifeng Pharmaceutical had a trading volume of 106,700 shares and a transaction value of 279 million yuan [1] - Dazhenglin recorded a trading volume of 72,200 shares with a transaction value of 126 million yuan [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 225 million yuan from institutional investors, while retail investors saw a net inflow of 205 million yuan [2] - Speculative funds had a net inflow of approximately 19.83 million yuan [2] Individual Stock Capital Flow - China Pharmaceutical had a net inflow of 20.91 million yuan from institutional investors, while it faced a net outflow of 8.68 million yuan from retail investors [3] - Liuyao Group saw a net inflow of 7.14 million yuan from institutional investors, but a net outflow of 10.03 million yuan from retail investors [3]

Core Viewpoint - Dazhonglin's stock price has shown a positive trend this year, with a notable increase in both revenue and net profit for the first half of 2025, indicating strong operational performance and investor interest [2][3]. Group 1: Stock Performance - As of September 17, Dazhonglin's stock price increased by 2.09% to 17.58 CNY per share, with a trading volume of 86.37 million CNY and a turnover rate of 0.43%, resulting in a total market capitalization of 20.02 billion CNY [1]. - Year-to-date, Dazhonglin's stock has risen by 19.19%, with a 1.62% increase over the last five trading days, a 2.33% increase over the last 20 days, and a 9.53% increase over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Dazhonglin achieved a revenue of 13.52 billion CNY, representing a year-on-year growth of 1.33%, while the net profit attributable to shareholders was 798 million CNY, reflecting a year-on-year increase of 21.38% [2]. - Since its A-share listing, Dazhonglin has distributed a total of 3.36 billion CNY in dividends, with 1.62 billion CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, Dazhonglin had 31,500 shareholders, a decrease of 10.07% from the previous period, with an average of 36,097 circulating shares per shareholder, an increase of 11.20% [2]. - The fourth largest circulating shareholder is Hong Kong Central Clearing Limited, holding 90.45 million shares, which is an increase of 12.43 million shares compared to the previous period [3].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [6] Core Views - The company has exceeded profit growth expectations through cost reduction and efficiency improvements [6] - In H1 2025, the company reported revenue of 13.523 billion yuan (up 1.33% year-on-year) and a net profit of 798 million yuan (up 21.38% year-on-year) [4][10] - The operating cash flow net amount reached 2.91 billion yuan (up 64.67% year-on-year) [4] Financial Performance Summary - In Q2 2025, the company achieved revenue of 6.567 billion yuan (down 0.41% year-on-year) and a net profit of 338 million yuan (up 30.49% year-on-year) [4][10] - The gross profit margin for H1 2025 was 34.86% (down 0.03 percentage points year-on-year), while the net profit margin increased to 5.90% (up 0.97 percentage points year-on-year) [11] - The company’s retail business revenue was 11.005 billion yuan (down 0.54% year-on-year), with a gross margin of 37.58% (up 0.36 percentage points year-on-year) [12] Business Segment Insights - The contribution of franchise business to revenue has increased, with franchise and distribution business revenue reaching 2.136 billion yuan (up 8.26% year-on-year) [12] - The sales of traditional Chinese and Western medicine increased, but the gross margin faced pressure [12] - The company opened 280 new stores in H1 2025, bringing the total number of stores to 16,833 [13] Future Projections - Revenue projections for 2025-2027 are 29.204 billion yuan, 32.542 billion yuan, and 36.075 billion yuan, with year-on-year growth rates of 10.22%, 11.43%, and 10.86% respectively [11] - The expected net profits for the same period are 1.081 billion yuan, 1.249 billion yuan, and 1.437 billion yuan, with growth rates of 18.20%, 15.52%, and 15.08% respectively [11]

北京市金杜（广州）律师事务所 关于大参林医药集团股份有限公司 2025 年第二次临时股东大会的法律意见书 致：大参林医药集团股份有限公司 北京市金杜（广州）律师事务所（以下简称本所）接受大参林医药集团股份有 限公司（以下简称公司）委托，根据《中华人民共和国证券法》（以下简称《证券 法》）、《中华人民共和国公司法》（以下简称《公司法》）、中国证券监督管理 委员会《上市公司股东会规则》（以下简称《股东会规则》）等中华人民共和国境 内（以下简称中国境内，为本法律意见书之目的，不包括中国香港特别行政区、中 国澳门特别行政区和中国台湾省）现行有效的法律、行政法规、规章和规范性文件 和现行有效的公司章程有关规定，指派律师出席了公司于 2025 年 9 月 15 日召开 的 2025 年第二次临时股东大会（以下简称本次股东大会），并就本次股东大会相 关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的以下文件，包括但不限于： 1 1． 经公司 2024 年年度股东大会审议通过的《大参林医药集团股份有限公司 章程》（以下简称《公司章程》）； 2． 公司 2025 年 8 月 28 日刊登于《中国证券报》《证 ...